STOCK TITAN

LeMaitre Vascular (LMAT) president sells 3,311.68 shares in open market trade

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.

The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Roberts David B

(Last) (First) (Middle)
C/O LEMAITRE VASCULAR, INC.
63 SECOND AVENUE

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and Director
3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/11/2026 S 3,311.68 D $107.6752(1) 14,667.32 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $106.52 to $108.65. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
/s/ Laurie A. Churchill, Attorney-in-fact 03/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LeMaitre Vascular (LMAT) report?

LeMaitre Vascular reported that President and Director David B. Roberts sold 3,311.68 shares of common stock in an open-market transaction on March 11, 2026, at a weighted average price of $107.6752 per share, according to a Form 4 insider filing.

How many LeMaitre Vascular (LMAT) shares did David B. Roberts sell and at what price?

David B. Roberts sold 3,311.68 LeMaitre Vascular common shares at a weighted average price of $107.6752. The filing notes these were multiple trades executed between $106.52 and $108.65, with the average price reported in the transaction details.

How many LeMaitre Vascular (LMAT) shares does David B. Roberts hold after this sale?

After the reported sale, David B. Roberts directly holds 14,667.32 shares of LeMaitre Vascular common stock. This post-transaction holding reflects his remaining direct ownership position as disclosed in the Form 4 filing for the March 11, 2026 transaction.

What role does David B. Roberts have at LeMaitre Vascular (LMAT)?

David B. Roberts serves as President and Director of LeMaitre Vascular. His position as both an executive officer and board member makes his equity transactions reportable, leading to this Form 4 disclosure of his March 11, 2026 open-market share sale.

Were the LeMaitre Vascular (LMAT) insider sales executed in a single trade or multiple trades?

The sales were executed in multiple trades, not a single transaction. The Form 4 states the reported price is a weighted average, with individual trades occurring between $106.52 and $108.65, and offers to provide full trade details upon request.

Does the LeMaitre Vascular (LMAT) Form 4 mention the price range for the insider sale?

Yes. The Form 4 footnote explains that the weighted average price of $107.6752 reflects multiple trades, with individual sale prices ranging from $106.52 to $108.65 for the common stock sold by David B. Roberts on March 11, 2026.
Lemaitre Vasculr

NASDAQ:LMAT

View LMAT Stock Overview

LMAT Rankings

LMAT Latest News

LMAT Latest SEC Filings

LMAT Stock Data

2.43B
20.80M
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
BURLINGTON